With increased survival after pediatric allogeneic hematopoietic SCT health-related quality of life (HRQL) has emerged as an essential health outcome. The impact of transplant and chronic GVHD (cGVHD)-associated morbidity remains a major obstacle. In 2005, the National Institutes of Health (NIH) Consensus Conference on Criteria for Clinical Trials in cGVHD recommended HRQL tools as an independent measure of the impact of disease burden. The NIH recommendations did not provide a cGVHD-specific tool for HRQOL measures in children. This report focuses on the development of an SCT-specific instrument to assess HRQL in children and adolescents. For the assessment of generic HRQL we chose the PedsQL (Pediatric Quality of Life Inventory) Generic Cores Scales, which have been used in a large number of healthy, acutely ill and chronically ill children and adolescents. To capture SCT-and, specifically, cGVHD-related problems, we developed the PedsQL Stem Cell Transplant module by reviewing the literature, taking over some items/scales of other PedsQL modules, interviewing patients, parents and members of the health-care team, and applying the PedsQL measurement methods. The final PedsQL Stem Cell Transplant module consists of the HRQL domains: pain and hurt, fatigue/sleeping problems/weakness, nausea, worry/anxiety about disease/treatment, nutritional problems, neurocognitive problems, communication about disease/treatment, loneliness, physical functioning and additional somatic complaints (pruritus, skin inflammation, oral problems, eyes or breathing) including patients' and parents' assessment. It was tested in 35 pediatric patients, who were referred to our SCT Outpatient Clinic about 100 days post SCT. Both the generic PedsQL and the SCT-specific scales showed high internal consistency, with Cronbach alpha levels of ⩾ 0.70 in almost all scales. Most problems were detected within the HRQL domains of physical functioning and pain. The summary scores of the generic PedsQL and the PedsQL Stem Cell Transplant module showed high correlations (r = 0.89 in patients' and r = 0.81 in parents' assessments). Moreover, both tools discriminated between patients with and without cGVHD. The PedsQL Stem Cell Transplant module is practical for use and suitable across a broad age range (2-18 years) both in patients with and without cGVHD. However, it is still a pilot instrument and needs further development and testing in a larger patient population.
INTRODUCTION
To standardize outcome measurement in patients receiving allogeneic hematopoietic SCT, specifically with regard to chronic GVHD (cGVHD), the National Institutes of Health (NIH) Consensus Conference on Criteria for Clinical Trials in cGVHD has published recommendations for the assessment of cGVHD. [1] [2] [3] The assessments should be as simple as possible to facilitate their use by clinicians and focus on the most important and most common manifestations of cGVHD. The proposed measures include clinician and patient reports, and are intended to improve consistency in the conduct and reporting of cGVHD for use in clinical trials. Whereas detailed recommendations have been provided for adults, cGVHD-specific tools for HRQL measures in children are still lacking.
After reviewing available health-related quality of life (HRQL) instruments and tools suggested for the use in pediatric patients, we decided, as a first step, to develop an instrument that would capture the disease-and treatment-related quality of life of patients who underwent SCT as scored according to their and/or their parents' perspective.
The generic Pediatric Quality of Life Inventory (PedsQL) is an HRQL instrument that includes 23 items and is suitable for use in healthy and ill children and adolescents. 4, 5 The German language versions of the generic PedsQL and the PedsQL Cancer Module were developed in our institution and used in different studies, including a longitudinal study with patients receiving SCT. [6] [7] [8] The PedsQL has excellent psychometric properties, is well accepted by patients and parents, easy to use and internationally recognized (an extensive list of publications can be found at: www.pedsql.org). Further, it is applicable across a wide age range; there are parent report versions of the PedsQL for children from the age of 2 years, as well as for adolescents up to an age of 18 years. For children aged between 5 and 7 years, the questionnaire can be completed with the assistance of an interviewer and the use of FACES scales. Starting at an age of 8 years, children are usually able to complete the PedsQL questionnaire without any problems.
Apart from pediatric cancer patients, the generic PedsQL was also successfully used in different clinical groups of severly ill children and adolescents undergoing transplantation, such as pediatric solid organ transplant recipients, 9 patients with betathalassemia, 10, 11 heart disease 12 or end-stage renal disease. 13 For the latter group, a disease-specific PedsQL module was developed to further elucidate disease-specific factors that affect patient HRQL. 14, 15 As we believed that neither the generic PedsQL nor the PedsQL Cancer Module capture all problems of patients after SCT, specifically not the symptoms and burden related to cGVHD, we decided to develop a new PedsQL module to be used in addition to the generic PedsQL. The members of the NIH cGVHD Consensus group were informed about our intention and agreed to it. The objectives of this publication are to describe the process of instrument development and to present the results from a pilot study testing the new PedsQL module in a cohort of pediatric SCT patients in an Austrian pediatric center.
PATIENTS AND METHODS
The PedsQL items ask about the frequency of problems that occurred during the past month. Response options are: never, almost never, sometimes, often and almost always. This response scale is easily understood by children. Like in the generic PedsQL the parents' questionnaire of the new module was designed to parallel the item content of the children's and adolescents' questionnaires. All new items should be phrased to allow their use within the PedsQL response scale.
The scores of each item and scale were converted to a 0-100 point scale with higher scores representing better functioning. James W Varni, who holds the copyright and the trademark for the PedsQL was part of the study team. The study was reviewed and approved by the local Institutional Review Board.
The development of the PedsQL Stem Cell Transplantation module was based on an extensive review of the literature and the views of patients, parents, physicians, nurses, psychologists and physiotherapists from our hospital leading to the generation of possible items for the new instrument. In addition, we included items of the PedsQL Cancer Module and the PedsQL Multidimensional Fatigue Scale. 4, 15 The details of the development of the module are provided in the Results section.
The proposed PedsQL Stem Cell Transplantation module was evaluated with pediatric patients after SCT and/or their parents presenting at our SCT outpatient clinic. Inclusion criteria were: patients ⩾ 2 years old, Germanspeaking, life expectancy of >3 months, at least 100 days post SCT, no evidence of recurrence of primary disease and written informed consent of parents and of patients ⩾ 8 years old. Patients and parents were asked to complete the questionnaire at baseline (day +100 after SCT or ongoing cGVHD without time limit) and then every 3 months. At all time points, cGVHD severity assessment (NIH cGVHD staging forms), disease status, comorbidities and medication were documented by the physician.
Here, we report the preliminary psychometric properties (feasibility, reliability and validity) of the new module. Cronbach's alpha coefficient was computed to evaluate the internal consistency reliability of the scales with a minimum acceptable criterion of 0.70. Construct validity was assessed by correlating the summary scores of the PedsQL Stem Cell Transplantation module with the PedsQL measuring generic HRQL, because a larger burden of disease-specific problems has been shown to be associated with a more compromised generic HRQL.
To test the discriminant validity of the new instrument, the treating physician assessed cGVHD signs and symptoms as published by the NIH Consensus Group. 1, 16 To evaluate whether the use of both the generic PedsQL and the PedsQL Stem Cell Transplantation module would be sufficient to capture all major symptoms of cGVHD, we asked patients to provide reports of their symptoms, if necessary with the assistance of their parents. This list of symptoms was then compared with items of the generic PedsQL and PedsQL Stem Cell Transplantation module.
RESULTS

Development of the new instrument
The development of the new instrument resulted in a list of 80 items. These 80 items were presented to a group of 30 patients from the SCT Outpatient Department aged ⩾ 8 years and 43 parents, who judged the incidence and importance of the specific problem referred to with each item. Specifically, respondents were asked to review each item and to provide feedback about the clarity of the wording and the relevance of the content. A rating scale was used to ascertain the perceived importance of each item for patient HRQL from the children's and parents' perspectives.
After data analysis, 39 of the original 80 items were eliminated. Reasons for elimination were: patients and/or parents thought the addressed problem was not important, items were not well understood or the addressed problem was already included in the generic PedsQL. Thus, the new PedsQL Stem Cell Transplantation module consisted of 41 items that were assigned to one of the eight domains in Table 1 .
Testing the new instrument
In 2010 and 2011, 35 SCT patients with a mean age of 10.5 (range, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] years were included in the process of testing the new instrument. These patients and their parents were not identical to those who participated in the developmental process (see above). The majority of patients and/or their parents completed the forms twice, with 3 or 6 months between the two assessments. Five of the 35 patients could not be included in both assessments due to early death (n = 2), transfer to another institution (n = 1), early recurrence (n = 1) or repeated transplantation (n = 1). An SCT-specific instrument to assess HRQL in pediatric patients
The time interval between study participation (completion of questionnaire) and SCT was a mean of 174 (range, 97-402) days. Altogether, 28% (10/35 patients) suffered from moderate or severe cGVHD at the time of the assessments.
None of the patients aged ⩾ 8 years or parents had difficulties in understanding the questions, and it took them 20-30 min to give their answers. For all the analyses, we considered only fully completed instrument questionnaires, resulting in 52 patient and 62 parent assessments. The results of the internal consistency reliability are summarized in Table 2 . The recommended standard (Cronbach alpha) of 0.70 or greater was exceeded in the majority of scales. The scales falling below this standard included 'school functioning' in the parent assessments (alpha = 0.63) and 'nausea' and 'communication' in the patient assessments ( = 0.62 and 0.68, respectively). Detailed results are shown in Table 2 .
The results from the descriptive analysis of the scale score distributions are summarized in Table 3 . Summary scores for each scale of the generic PedsQL and the PedsQL module were computed as the average of individual scale scores. Because a considerable number of patients were not yet attending school, the fewest responses were obtained for the items addressing school functioning. Therefore, those were not included in the calculation of the summary score of the generic PedsQL. All scales were negatively skewed, indicating distributions with more respondents scoring along the positive end of scales.
The lowest scale scores were seen in physical functioning, and in pain and hurt (see Table 3 ). The summary scores of the generic PedsQL and the PedsQL Stem Cell Transplantation module showed high correlations: r = 0.89 in patients' and r = 0.81 in parents' assessments, giving evidence that the module also measures what it is supposed to measure, that is, HRQL.
The comparison of summary scores of the two groups of patients with and without cGVHD is shown in Figure 1 . Owing to the small sample size, the different overall severity of cGVHD scores as well as organ-specific cGVHD scores were not included in the analyses. In all assessments, the scores of patients with cGVHD were significantly lower (P ⩽ 0.01) in terms of more compromised HRQL than those of patients without cGVHD. Specifically, in patients with and without cGVHD, the summary scores were 71.5 vs 83.2 (generic PedsQL, parent reports), 77.6 vs 87.4 (generic PedsQL, patient reports), 77.6 vs 88.9 (PedsQL Stem Cell Transplantation module, parent reports) and 79.2 vs 90.4 (PedsQL Stem Cell Transplantation module, patient reports).
To evaluate whether the use of both the generic PedsQL and the SCT module would be sufficient to capture all major symptoms of cGVHD, we asked patients, with the assistance of their parent(s), to report all the symptoms that they were suffering from. The list of reported symptoms can be found in Table 4 .
On comparing reported symptoms with the items of the generic PedsQL and PedsQL Stem Cell Transplantation module, we found that the majority of symptoms were covered by items of the two questionnaires, specifically motion problems, pain in various body locations, emotional problems, sleeping disturbances, loss of energy, physical weakness, pruritus, painful skin infections, dry mouth, dry eyes, breathing problems and others. However, some important symptoms listed in Table 4 were not addressed in the generic PedsQL and the PedsQL Stem Cell Transplantation module, such as muscle cramps, specific genital tract problems or bad eyesight, suggesting that the scale 'other complaintsspecifically cGVHD-related problems' of the module should be complemented with these or other additionally observed symptoms in the future.
DISCUSSION
The novelty of this study is the successful development and first use of a new, therapy-specific PedsQL module measuring HRQL after SCT that is suitable for both children and adolescents across a broad age range of 2-18 years. This new instrument both covers SCT-specific issues and cGVHD-specific symptoms and disease burden. There is convincing evidence that cGVHD is the major risk factor for reduced HRQL and impaired functional status after SCT. 17, 18 However, diagnosis and determination of therapeutic response is a major challenge in cGVHD, as the clinical manifestations of the disease are incredibly diverse. Therefore, the published NIH consensus criteria, addressing the areas of diagnosis and staging, histopathology, strategies for the development and validation of biomarkers, response criteria, ancillary therapy and supportive care, and the design of clinical trials are an important effort to improve the assessment of cGVHD including the effect on HRQL. [19] [20] [21] The recommendations of the NIH cGVHD Consensus Group include the use of self-report measures, but do not provide recommendations for pediatric cGVHD-specific tools for the measurement of HRQL. 1, 3 Recommended tools like the Lee symptom scale for adults, the SF-36 and the FACT-BMT have shown good correlation with different cGVHD severity scores but clearly there are no pediatric instruments. [22] [23] [24] [25] HRQL measures should be easy to administer and give preference to quantitative, rather than semiquantitative data. HRQL is a widely acknowledged clinical outcome criteria, and many instruments have been developed and validated. 26 In pediatrics, the methodological challenge in measuring HRQL is that, an instrument must account for the continuous physical, emotional, social and cognitive development during childhood and adolescence. 8 The PedsQL by James W Varni is among the most widely used measures worldwide. Although children and adolescents have different concerns related to HRQL, the items selected for the generic PedsQL, which can be used in healthy as well as ill children and adolescents, reflect those items that are of universal concern across age groups. 4 However, the generic PedsQL is not a cGVHD-specific instrument and cannot yield detailed information for specific factors that have an impact on HRQL in pediatric patients with cGVHD.
Therefore, we developed a PedsQL Stem Cell Transplantation module so that the generic PedsQL and the new scales could be Abbreviations: cGVHD = chronic GVHD; n = number of complete assessments; PedsQL = Pediatric Quality of Life Inventory.
An SCT-specific instrument to assess HRQL in pediatric patients A Lawitschka et al easily combined. Our primary intention was to develop a questionnaire for specific use in pediatric patients after SCT including those with cGVHD. The new PedsQL Stem Cell Transplantation module may still lack some items addressing specific cGVHD symptoms. Future revisions of the scales can be informed by new research and publications such as the work of Wiener et al. 27 who used qualitative methods to identify the phrases, terms and constructs that children and adolescents employ when describing their cGVHD symptoms.
Nevertheless, first results on the psychometric criteria of the PedsQL Stem Cell Transplantation module, specifically on internal consistency reliability, construct validity and discriminant validity, are promising. Most importantly, it seems to differentiate between patients with and without cGVHD. The observed skewed score distributions toward the positive end of scales, both for the new instrument and the generic PedsQL is frequently seen in clinical research and has been reported in other studies. 8 Such skewed distributions occur when a measure does not distinguish between a person who does extremely well and a person who does well. This differentiation is negligible in clinical research, especially in severely ill patients. However, the skewed score distributions and the relatively high mean scores may raise doubts about the Abbreviations: cGVHD = chronic GVHD; m = mean; n = number of complete assessments; PedsQL = Pediatric Quality of Life Inventory. An SCT-specific instrument to assess HRQL in pediatric patientsvalidity of findings in HRQL studies. Therefore, such measures cannot be used without taking into account the phenomenon of 'response shift'. Response shift means that there is an adaptation of the perception of HRQL that occurs as a result of a change in the internal standards (recalibration), a change in personal values (reprioritization) or a change in the definition of the construct (reconceptualization). 18, 19 Response shift, however, should not affect outcomes of validity testing.
This pilot study has some limitations such as the small sample size and the cross-sectional design. Because of the limited number of included patients, the different NIH global severity stages as well as the organ-specific severity scores could not be considered.
In summary, the data presented here provide evidence of the new PedsQL module's ability to depict the HRQL in patients receiving SCT and their disease-and therapy-related problems in combination with the generic PedsQL. It is practical in daily clinical routine and was well accepted by patients and parents. Validation within a larger cohort of patients is highly warranted including analysis of the discriminating items regarding the global NIH severity stages and the organ-specific severity scores.
A multicenter study, validating the PedsQL Stem Cell Transplantation module including analysis of the correlation between the phycian's and patient's perception of change of NIH cGVHD scores and outcome is currently on the way.
